Core Viewpoint - Jinfang Pharmaceutical-B (2595.HK) debuted on the Hong Kong Stock Exchange today, opening 115.79% higher at HKD 44, with a market capitalization of HKD 15.2 billion [1] Company Overview - Jinfang Pharmaceutical was established in 2017, focusing on developing new treatment solutions for oncology (covering various solid tumors) as well as autoimmune and inflammatory diseases [1] Financial Performance - In the first four months of 2023, 2024, and 2025, the company reported revenues of CNY 74 million, CNY 105 million, and CNY 82 million respectively [1] - Research and development expenditures for the same periods were CNY 313 million, CNY 332 million, and CNY 69.8 million respectively [1] - The net losses for these periods were CNY 508 million, CNY 678 million, and CNY 66 million, totaling over CNY 1.2 billion in losses over two years [1] Product Development - Jinfang Pharmaceutical currently has one core product, GFH925 (brand name: Daberut), which has been approved for market launch [1] - The commercialization of GFH925 in the domestic market relies on partnerships, and in January 2024, the company terminated the overseas option under the licensing agreement with Innovent Biologics, requiring a refund of USD 20 million [1]
港股异动丨劲方医药首日上市高开115%
Ge Long Hui·2025-09-19 01:48